UC San Diego School of Medicine, Continuing Medical Education
(858) 534-3940 | ocme@ucsd.edu | cme.ucsd.edu

We are hosting the fifth international Veterinary Pain Short Course on pain, pain mechanisms and novel therapies in veterinary medicine, August 22-25, 2018 in San Diego, CA. This meeting is unique in veterinary medicine for its emphasis upon fundamental (basic) principles and mechanisms of pain as they pertain to the veterinary patient.  

Pain in the veterinary patient is a rich and complex phenomenon. The development of therapeutics to manage that pain state has been a subject of great interest, and advances in therapeutics reflects upon the growth in our understanding of the basic mechanisms in pain processing. 

Interest in pain and its management is a natural focus of the veterinary profession as mandated by the AVMA and the standards set by the AAHA/AAFP and practiced by the International Veterinary Association for Pain Management (IVAPM). 

Intense interest in this issue is also reflected by the increased interest in pain management products by animal care divisions of most veterinary pharma companies and by the broad interest by those in veterinary medicine who attend and participate in pain focused conferences, such as the one being undertaken here. 

Target Audience

This course was designed for veterinarians and animal researchers interested in the study of pain in animals and humans and for pharmaceutical researchers and companies interested in the development of veterinary analgesics.

Course Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate the current knowledge of timely and noteworthy topics related to the physiologic basis of pain and nociceptive processing.
  • Review current issues in determining quality of life and pain assessment instruments in veterinary practice.
  • Provide insight into the development of current and future novel therapeutics in clinical pain management.
  • Explain the development process for veterinary pain therapeutics from the perspective of the drug developer and the Center for Veterinary Medicine at the FDA.